A. August 2020.
A study in Australia revealed that: It is uncertain if the increased retinal activity in the retina with high doses of nicotinamide, (Vit. B3), translate to meaningful change to the daily lives of people with glaucoma. Larger multisite trials are needed.
Prof. Crowston, J & Dr Hui, F., Centre for Eye Research, August 2020.
and :
B. 23 February 2022
A major four-year clinical trial to test the effectiveness of nicotinamide, a form of vitamin B3, as a treatment for glaucoma is to be led by UCL and Moorfields Eye Hospital researchers.
and:
C. 14 October 2024.
Nicotinamide (vitamin B3) has shown promise as a potential therapeutic approach for glaucoma. Recent studies suggest that nicotinamide may help protect RGCs, (retinal ganglion cells), by enhancing mitochondrial function, reducing oxidative stress, and supporting cell energy production. By bolstering cellular defenses and preventing further damage to the optic nerve, nicotinamide could play a key role in neuroprotection for glaucoma patients, potentially slowing disease progression and preserving vision.
by Tonia S. Rex, PhD
Tonia Rex, PhD is Vice Chair for Basic and Translational Research and Marlene and Spencer Hays Director in Translational Vision Research, Department of Ophthalmology and Visual Sciences, at Vanderbilt University Medical Center in Nashville, Tennessee.
My conclusion: It's too early to say, but we can live in hope.
PW.